Core Viewpoint - The company is focused on the ecological layout in the pharmaceutical and health industry, with its main business covering pharmaceutical distribution, digital empowerment, and health services [1] Summary by Categories Business Focus - The company will concentrate on its core strategy and continue to deepen its layout across the entire pharmaceutical health industry chain [1] Current Collaborations - As of now, the company has no business cooperation arrangements with military enterprises [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所发布的上市公司分行业信息披露指引及《关于做好主板 上市公司 2025 年第三季度报告披露工作的重要提醒》相关要求，现将公司 2025 年前三季度主要经营数据披露如下： 一、报告期内，公司主营业务收入按分行业经营情况如下： 注：此表中收入类别的"其他"主要系全资子公司北京康惠智创科技有限公司的相关数 据，该子公司 2025 年 5 月设立，无上年数据。 二、报告期内，公司主营业务收入按产品用途经营情况如下： 证券代码：603139 证券简称：康惠股份 公告编号：2025-071 陕西康惠制药股份有限公司 关于2025年前三季度主要经营数据的公告 单位：万元 项 目 营业收入 营业成本 毛利率（%） 营业收入比上 年增减（%） 营业成本比上 年增减（%） 毛利率比上 年增减(%) 本公告之经营数据未经审计，提醒投资者审慎使用上述数据，注意投资风险。 陕西康惠制药股份有限公司董事会 2025 年 10 月 30 日 妇科类 2,494.58 1,165.74 53.2 ...

Group 1 - The core point of the article is that Kanghui Pharmaceutical announced significant shareholding and pledge details from a major shareholder, along with its revenue composition for the first half of 2025 [1] Group 2 - Kanghui Pharmaceutical's major shareholder, Shanghai Chuangxiangying Enterprise Management Partnership, holds approximately 5.99 million shares, accounting for 6% of the total share capital [1] - As of the announcement date, Chuangxiangying has pledged about 4 million shares, which is 66.67% of its holdings and 4% of the total share capital [1] - For the first half of 2025, Kanghui Pharmaceutical's revenue composition is as follows: 60.68% from pharmaceutical manufacturing, 36.79% from pharmaceutical distribution, and 2.53% from other businesses [1] - The current market capitalization of Kanghui Pharmaceutical is 2.4 billion yuan [1]

Group 1 - The company Guofa Co., Ltd. (SH 600538) announced the convening of its 11th Board of Directors' 17th meeting on July 31, 2025, to discuss the election of new committee members [2] - For the fiscal year 2024, the revenue composition of Guofa Co., Ltd. is as follows: pharmaceutical distribution accounts for 53.64%, judicial appraisal for 34.87%, pharmaceutical manufacturing for 10.41%, other businesses for 0.64%, and other categories for 0.44% [2]